other:Article Title: Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
Article Snippet: Triplicate wells of ELISA microtiter plates (Nunc Immuno plates MaxiSorp: Invitrogen Cat #4-39454A) were coated with 100 μl/well of the following cytokines: recombinant huIL1β (Novartis), recombinant huIL-3 (R&D Systems® Cat #203-IL/CF), recombinant huIL-4 (R&D Systems® Cat #204-IL/CF), recombinant huIL-6 (R&D Systems® Cat #206-IL-1010/CF), recombinant huIL-8 (R&D Systems® Cat #208-IL-010/CF), recombinant huIL-12 (R&D Systems® Cat #219-IL-005/CF), recombinant huIL-13 (Novartis), recombinant huIL-17A (SEQ ID NO: 76), recombinant huIL-17A/F, recombinant huIL-17F (SEQ ID NO: 77), recombinant huIL-18 (MBL Cat # B003-5), recombinant huIL-20 (Novartis), recombinant huIL-23 (R&D Systems® Cat #1290-IL-010/CF), recombinant huIFNγ (Roche), recombinant huTNFα (Novartis), recombinant huEGF (Sigma Cat # E9644), recombinant huTGFβ2 (Novartis), recombinant mIL-1β (R&D Systems® Cat #401-ML), recombinant mIL-2 (R&D Systems® 402-ML-020/CF), recombinant mIL-6 (R&D Systems® Cat #406-ML-010/CF), recombinant mIL-12 (R&D Systems® Cat #419-ML-010/CF), recombinant mIL-17A (SEQ ID NO: 83), recombinant mIL-17A/F (R&D Systems® Cat #5390-IL), recombinant mIL-17F (R&D Systems® Cat #2057-IL/CF), recombinant mIL-18 (MBL Cat # B004-5), recombinant mIL-23 (R&D Systems® Cat #1887-ML), recombinant mIFN-γ (R&D Systems® Cat #485-MT), recombinant mTNFα (R&D Systems® Cat #410-MT), recombinant rat IL-4 (R&D Systems® Cat #504-RL/CF), recombinant rat IL-6 (R&D Systems® Cat #506-RL-010), recombinant ratIL-12 (R&D Systems® Cat #1760-RL/CF), recombinant ratIL-17A (SEQ ID NO: 85), recombinant ratIL-23 (R&D Systems® Cat #3136-RL-010/CF), recombinant ratTNFα (R&D Systems® Cat #510-RT/CF), at 1 μg/ml with the exception of recombinant mIL-6, recombinant mIL-12 and recombinant mTNFα which were coated at 0.5 μg/ml in phosphate buffered saline (PBS) without Ca and Mg (10×; Invitrogen Cat #14200-083) 0.02% NaN3 (Sigma Cat # S-8032) and incubated overnight at 4° C. The following day, microtiter plates were blocked with 300 μl of PBS/2% BSA (fraction V; Roche Cat #10 735 094 001)/0.02% NaN3 for 1 h at 37° C. Plates were then washed 4 times with PBS/0.05% Tween 20 (Sigma Cat # P7949)/0.02% NaN3.
Article Title: Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory
Article Snippet: Triplicate wells of ELISA microtiter plates (Nunc Immuno plates MaxiSorp: Invitrogen Cat#4-39454A) were coated with 100 μl/well of the following cytokines: recombinant huIL1β (Novartis), recombinant huIL-3 (R&D Systems® Cat#203-IL/CF), recombinant huIL-4 (R&D Systems® Cat#204-IL/CF), recombinant huIL-6 (R&D Systems® Cat#206-IL-1010/CF), recombinant huIL-8 (R&D Systems® Cat#208-IL-010/CF), recombinant huIL-12 (R&D Systems® Cat#219-IL-005/CF), recombinant huIL-1β (Novartis), recombinant huIL-17A (SEQ ID NO: 76), recombinant huIL-17A/F, recombinant huIL-17F (SEQ ID NO: 77), recombinant huIL-18 (MBL Cat#B003-5), recombinant huIL-20 (Novartis), recombinant huIL-23 (R&D Systems® Cat#1290-IL-010/CF), recombinant huIFNγ (Roche), recombinant huTNFα (Novartis), recombinant huEGF (Sigma Cat#E9644.), recombinant huTGFβ2 (Novartis), recombinant mIL-1β (R&D Systems® Cat#401-ML), recombinant mIL-2 (R&D Systems® 402-ML-020/CF), recombinant mIL-6 (R&D Systems® Cat#406-ML-010/CF), recombinant mIL-12 (R&D Systems® Cat#419-ML-010/CF), recombinant mIL-17A (SEQ ID NO: 83), recombinant mIL-17A/F (R&D Systems® Cat#5390-IL), recombinant mIL-17F (R&D Systems Cat#2057—IL/CF), recombinant mIL-18 (MBL Cat#B004-5), recombinant mIL-23 (R&D Systems® Cat#1887-ML), recombinant mIFN-γ (R&D Systems® Cat#485-MT), recombinant mTNFα (R&D Systems® Cat#410-MT), recombinant rat IL-4 (R&D Systems® Cat#504-RL/CF), recombinant rat IL-6 (R&D Systems® Cat#506-RL-010), recombinant ratIL-12 (R&D Systems® Cat#1760-RL/CF), recombinant ratIL-17A (SEQ ID NO: 85), recombinant ratIL-23 (R&D Systems® Cat#3136-RL-010/CF), recombinant ratTNFα (R&D Systems® Cat#510-RT/CF), at 1 μg/ml with the exception of recombinant mIL-6, recombinant mIL-12 and recombinant mTNFα which were coated at 0.5 μg/ml in phosphate buffered saline (PBS) without Ca and Mg (10×; Invitrogen Cat#14200-083) 0.02% NaN3 (Sigma Cat#S-8032) and incubated overnight at 4′C.
Article Title: Nucleic acid encoding anti-IL-17A antibodies
Article Snippet: Triplicate wells of ELISA microtiter plates (Nunc Immuno plates MaxiSorp: Invitrogen Cat#4-39454A) were coated with 100 μl/well of the following cytokines: recombinant huIL1β (Novartis), recombinant huIL-3 (R&D Systems® Cat#203-IL/CF), recombinant huIL-4 (R&D Systems® Cat#204-IL/CF), recombinant huIL-6 (R&D Systems® Cat#206-IL-1010/CF), recombinant huIL-8 (R&D Systems® Cat#208-IL-010/CF), recombinant huIL-12 (R&D Systems® Cat#219-IL-005/CF), recombinant huIL-13 (Novartis), recombinant huIL-17A (SEQ ID NO: 76), recombinant huIL-17A/F, recombinant huIL-17F (SEQ ID NO: 77), recombinant huIL-1β (MBL Cat# B003-5), recombinant huIL-20 (Novartis), recombinant huIL-23 (R&D Systems® Cat#1290-IL-010/CF), recombinant huIFNγ (Roche), recombinant huTNFα (Novartis), recombinant huEGF (Sigma Cat#E9644.), recombinant huTGF62 (Novartis), recombinant mIL-1β (R&D Systems® Cat#401-ML), recombinant mIL-2 (R&D Systems® 402-ML-020/CF), recombinant mIL-6 (R&D Systems® Cat#406-ML-010/CF), recombinant mIL-12 (R&D Systems® Cat#419-ML-010/CF), recombinant mIL-17A (SEQ ID NO: 83), recombinant mIL-17A/F (R&D Systems® Cat#5390-IL), recombinant mIL-17F (R&D Systems® Cat#2057-IL/CF), recombinant mIL-1β (MBL Cat#B004-5), recombinant mIL-23 (R&D Systems® Cat#1887-ML), recombinant mIFN-γ (R&D Systems® Cat#485-MT), recombinant mTNFα (R&D Systems® Cat#410-MT), recombinant rat IL-4 (R&D Systems® Cat#504-RL/CF), recombinant rat IL-6 (R&D Systems® Cat#506-RL-010), recombinant ratIL-12 (R&D Systems® Cat#1760-RL/CF), recombinant ratIL-17A (SEQ ID NO: 85), recombinant ratIL-23 (R&D Systems® Cat#3136-RL-010/CF), recombinant ratTNFα (R&D Systems® Cat#510-RT/CF), at 1 μg/ml with the exception of recombinant mIL-6, recombinant mIL-12 and recombinant mTNFα which were coated at 0.5 μg/ml in phosphate buffered saline (PBS) without Ca and Mg (10×, Invitrogen Cat#14200-083) 0.02% NaN3 (Sigma Cat# S-8032) and incubated overnight at 4° C. The following day, microtiter plates were blocked with 300 μl of PBS/2% BSA (fraction V; Roche Cat#10 735 094 001)/0.02% NaN3 for 1 h at 37° C. Plates were then washed 4 times with PBS/0.05% Tween 20 (Sigma Cat# P7949)/0.02% NaN3.
Enzyme-linked Immunosorbent Assay:Article Title: Immune mechanisms of resistance to cediranib in ovarian cancer
Article Snippet: The slides were left to dry and imaged using confocal microscopy (Zeiss LSM 510 META). .. ELISA Mouse IL-6 cytokine concentrations in MLEC treated with recombinant mIL-6 and cediranib were measured using Quantikine ELISA kit (R&D systems) according to the manufacturer’s protocol. .. Absorbance were measured at 450 nm using an Opsys MR plate reader (Dynex Technologies).
Article Title: Immune mechanisms of resistance to cediranib in ovarian cancer
Article Snippet: The slides were left to dry and imaged using confocal microscopy (Zeiss LSM 510 META). .. Mouse IL-6 cytokine concentrations in MLEC treated with recombinant mIL-6 and cediranib were measured using Quantikine ELISA kit (R&D systems) according to the manufacturer’s protocol. .. Absorbance were measured at 450 nm using an Opsys MR plate reader (Dynex Technologies).
Recombinant:Article Title: Immune mechanisms of resistance to cediranib in ovarian cancer
Article Snippet: The slides were left to dry and imaged using confocal microscopy (Zeiss LSM 510 META). .. ELISA Mouse IL-6 cytokine concentrations in MLEC treated with recombinant mIL-6 and cediranib were measured using Quantikine ELISA kit (R&D systems) according to the manufacturer’s protocol. .. Absorbance were measured at 450 nm using an Opsys MR plate reader (Dynex Technologies).
Article Title: Immune mechanisms of resistance to cediranib in ovarian cancer
Article Snippet: The slides were left to dry and imaged using confocal microscopy (Zeiss LSM 510 META). .. Mouse IL-6 cytokine concentrations in MLEC treated with recombinant mIL-6 and cediranib were measured using Quantikine ELISA kit (R&D systems) according to the manufacturer’s protocol. .. Absorbance were measured at 450 nm using an Opsys MR plate reader (Dynex Technologies).
|
R&D Systems is a verified supplier 
R&D Systems manufactures this product 